Mayo Clinic research identified a powerful new way to improve the prediction of a patient’s long-term cardiovascular disease risk by enhancing a routinely performed imaging test with artificial intelligence (AI). Heart disease develops over time and remains the leading cause of death
Cardiovascular
According to the American Heart Association (AHA) and the World Health Organization (WHO), the Eastern Mediterranean Region (EMR), which includes most Middle East and North Africa (MENA) countries, is now among the regions with the highest prevalence of cardiovascular diseases (CVDs) globally, with a sharp rise attributed to preventable, lifestyle-related risk factors such
Eli Lilly and Company (NYSE: LLY) today announceli ed topline results from SURPASS-CVOT, a first-of-its-kind head-to-head Phase 3 cardiovascular outcomes trial comparing two incretin therapies in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, was compared to Trulicity












